In this context, Yang et al. demonstrated that the combination of low-dose CDK4/6 and FLT3 inhibitors helped to overcome TKI resistance and successfully reduced AML cell growth in vitro [42]. This evidence concerns the gene CDK4 and acute myeloid leukemia.